Prof. Helen McShane

Prof. Helen McShane leads the TB vaccine programme at Oxford University and is working on a BCG challenge model. MVA85A, the original new TB vaccine she developed at Oxford, is currently in clinical trials in the UK, The Gambia, Senegal and South Africa and is one of the world’s leading new TB vaccines. An infant Phase IIb efficacy trial with this vaccine in South Africa commenced in April 2009 in collaboration with the South African TB Vaccine Initiative and Aeras Global TB Foundation. 
Prof. McShane trained in medicine at Guy’s Hospital, London, and was awarded an MRC Clinical Training Fellowship in 1997. She then undertook a PhD with Professor Adrian Hill in Oxford investigating prime-boost immunisation strategies in the murine model of tuberculosis. She became a consultant in HIV and genito-urinary medicine in 2003 and was awarded a Wellcome Trust Senior Clinical Fellowship in June 2005. Currently she is a Fellow of the Royal College of Physicians in London and Professor of Vaccinology at the University of Oxford.